It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
The goal for the project is the identification and optimization of anti-viral compounds.
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
This work has been published in the journal ‘ACS applied materials and interface’
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
CDSCO to fast-track trials and approval for COVID19 vaccine
Centre at Sree Chitra Tirunal Institute for Medical Sciences and Technology
Subscribe To Our Newsletter & Stay Updated
